期刊
MEDCHEMCOMM
卷 8, 期 8, 页码 1659-1667出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c7md00247e
关键词
-
资金
- Intramural Research Program of the NIH, National Institute of Diabetes and Digestive and Kidney Diseases
- Inserm, Univ. Lille, France
- UGC, India
- National Heart, Lung, and Blood Institute [R01HL133589]
A pyrazolo[4,3-e][1,2,4] triazolo[1,5-c] pyrimidin-5-amine antagonist of the A(2A) adenosine receptor (AR) was functionalized as amine congeners, fluorescent conjugates and a sulfonate, and the A(2A)AR binding modes were predicted computationally. The optimal n-butyl spacer was incorporated into the following A(2A)AR-selective (K-i, nM) conjugates: BODIPY630/650 derivative 11 (MRS7396, 24.6) and AlexaFluor488 derivative 12 (MRS7416, 30.3). Flow cytometry of 12 in hA(2A)AR-expressing HEK-293 cells displayed saturable binding (low nonspecific) and inhibition by known A(2A)AR antagonists. Water-soluble sulfonate 13 was a highly potent (K-i = 6.2 nM) and selective A(2A)AR antagonist based on binding and functional assays. Docking and molecular dynamics simulations predicted the regions of interaction of the distal portions of these chain-extended ligands with the A(2A)AR. The BODIPY630/650 fluorophore of 11 was buried in a hydrophobic interhelical (TM1/TM7) region, while AlexaFluor488 of 12 associated with the hydrophilic extracellular loops. In conclusion, we have identified novel high affinity antagonist probes for A(2A)AR drug discovery and characterization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据